First Brain-Penetrant GD3 Approval Rests on 43-Patient Neurologic Win
Regulatory Approvals

First Brain-Penetrant GD3 Approval Rests on 43-Patient Neurologic Win

Published : 19 Nov 2026

At a Glance
IndicationNeurological symptoms of Type 3 Gaucher disease
Drugvenglustat
Mechanism of Actionglucosylceramide synthase inhibitor
CompanyGenzyme Corporation, a Sanofi Company
CategoryRegulatory Milestone
Sub CategoryApproval Granted
Therapeutic AreaRare Diseases & Genetics
Approval DateNovember 18, 2026
Regulatory AgencyU.S. Food and Drug Administration
Approved Market/RegionU.S.
Review DesignationOrphan Drug designation, Priority Review
Patient Populationadults and pediatric patients weighing at least 15 kg
Patient Subpopulationpatients aged 12 years and older with GD3 who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization
Study Designrandomized, double-blind, multicenter clinical study
Number of Patients43
Treatment Duration52 weeks
Comparatorintravenous enzyme replacement therapy
Key Assessmentsataxia and cognitive function

FDA Approves Infilbray for Neurological Symptoms of Type 3 Gaucher Disease

The U.S. FDA has approved Infilbray (venglustat) tablets, marking the first treatment for neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. Infilbray, a glucosylceramide synthase inhibitor, uniquely crosses the blood-brain barrier to reduce the accumulation of harmful glucosphingolipids in both the body and brain. This approval is supported by a 52-week randomized, double-blind, multicenter clinical study involving 43 GD3 patients (aged 12+) previously on enzyme replacement therapy, where Infilbray demonstrated improvement in combined ataxia and cognitive function assessments compared to enzyme replacement therapy alone. The drug received Orphan Drug designation and Priority Review.

  • Targeted Mechanism and Blood-Brain Barrier Penetration: Infilbray (venglustat) is a novel glucosylceramide synthase inhibitor designed to reduce the buildup of harmful glucosphingolipids. Crucially, it is the first treatment for Type 3 Gaucher disease that can cross the blood-brain barrier, directly addressing the neurological symptoms by targeting the accumulation of these substances within the brain, a key differentiator from previous systemic therapies.
  • Pivotal Clinical Study Outcomes: The FDA's approval is based on a 52-week randomized, double-blind, multicenter clinical study involving 43 patients aged 12 years and older with GD3. These patients, who had achieved systemic disease stabilization on prior enzyme replacement therapy, showed significant improvement on a combined measure of ataxia and cognitive function assessments when treated with Infilbray orally once daily, compared to those receiving only intravenous enzyme replacement therapy.
  • Regulatory Designations and Patient Population: Infilbray was granted both Orphan Drug designation and Priority Review by the FDA, underscoring its importance for a rare condition with unmet medical needs. The approval specifically covers adults and pediatric patients weighing at least 15 kg, expanding therapeutic options for a broad range of patients suffering from the debilitating neurological manifestations of Type 3 Gaucher disease.

The Critical Unmet Need in Type 3 Gaucher Disease Neurological Symptoms

Current treatment approaches for Type 3 Gaucher disease effectively address systemic disease but leave neurological symptoms largely refractory. Enzyme replacement therapy and substrate reduction therapy ameliorate systemic features, but no therapies are approved for neurological manifestations and efficacies in treating the neurological manifestations are negligible.

  • Inability to cross the blood-brain barrier: Recombinant enzymes do not cross the blood-brain barrier and therefore are not expected to lead to any improvement in CNS damages. Enzyme replacement therapy is unable to prevent neurological progression as the enzyme cannot cross the blood-brain barrier, and in the setting of progressive neurological symptoms such as seizures and or neuroregression, enzyme replacement therapy is not recommended.

  • Persistence of neurological progression despite systemic control: Clinical findings including hepatosplenomegaly, thrombocytopenia, and skeletal findings improved following enzyme replacement therapy, except for the neurological manifestations. Neurologic manifestations including oculomotor apraxia, dystonia, and seizures emerged despite continued enzyme replacement therapy, and neurocognition assessed by Vineland II deteriorated in all domains over time, which illustrates disease progression despite the intervention.

  • Poor seizure control and sudden death on therapy: Twenty-three patients (30%) developed seizures while on enzyme replacement therapy for 1-9 years, of those 12 patients (15%) died suddenly and unexpectedly at a mean age of 6.7 ± 5.0 years. Seizure control remained poor despite multiple antiseizure medications and vagus nerve stimulation (VNS).

  • Dependence on a single modality with limited CNS distribution: Enzyme replacement therapy successfully treats the hematologic manifestations; however, due to the lack of equal distribution of the recombinant enzyme in different organs, it has no direct impact on the nervous system and has minimal effect on bone involvement. Beyond enzymes not being able to traverse the blood-brain barrier, dependence on a single modality is problematic since not all patients are responders, some develop adverse events, and supply may not be forthcoming for non-medical reasons.

Infilbray's Pivotal Study Design and Efficacy in GD3 Neurological Symptoms

Neurological symptoms in type 3 Gaucher disease (GD3) have been evaluated in a pilot chaperone study, retrospective national cohorts, and disease registries. Designs include open-label intervention, multicenter retrospective chart review, and prospective plus retrospective observational follow-up. Endpoints span biochemical markers, standardized motor and functional scales, and neurophysiological and imaging assessments.

Study Population Design Parameters Endpoints
Ambroxol pilot, 5 patients with neuronopathic GD receiving high-dose oral ambroxol in combination with enzyme replacement therapy, open-label pilot study High-dose oral ambroxol plus enzyme replacement therapy; safety by adverse event query, physical examination, electrocardiography, laboratory studies, and drug concentration Biochemical efficacy through glucocerebrosidase activity in the lymphocytes and glucosylsphingosine levels in the cerebrospinal fluid; neurological efficacy using Unified Myoclonus Rating Scale, Gross Motor Function Measure, Functional Independence Measure, seizure frequency, pupillary light reflex, horizontal saccadic latency, and electrophysiologic studies
Italian cohort, 10 patients (6 females, 4 males) with four genotypes (L444P/L444P, L444P/F231I, P159T/unknown, C.115+1G>A/N188S) followed in 4 centres (Udine, Catanzaro, Sassari and Florence), ERT infusions from 3 to 21 years All patients affected by GD3 treated with ERT included; data collected retrospectively from clinical records Clinical conditions, laboratory values, neurological and neuropsychological examinations, radiological and electrophysiological features; haematological parameters and organomegaly; progression to central nervous system disease, progressive myoclonic encephalopathy, and epileptiform abnormalities at the electroencephalogram
Spanish cohort, 19 patients with GD3 from 10 Spanish hospitals (14 men, 5 women), median age at onset 1 year and at diagnosis 1.2 years, mean age at follow-up 12.37 years (range: 1-25 years) Retrospective, multicenter study of genotype, phenotype, therapeutic options, and treatment responses; all patients received enzyme replacement therapy; other treatments included miglustat and ambroxol Visceral manifestations including splenomegaly (18/19) and hepatomegaly (17/19); neurological abnormalities at onset including psychomotor retardation (14/19) and extrinsic muscle disorders (11/19), including oculomotor apraxia, supranuclear palsy, and strabismus; L444P (c.1448T>C) allele predominance
Gaucher Outcome Survey, 26 patients reported as GD3 of 1002 enrolled as of October 2015, international registry established in 2010 International disease-specific registry for patients with confirmed diagnosis regardless of GD type or treatment status; majority from US (13; 50.0%), UK (seven; 26.9%), Israel (three; 11.5%), Brazil (three; 11.5%); median age of symptom onset 1.4 years (interquartile range: 0.5-2.0 years) GBA1 mutation genotype L444P/L444P in 16 (69.6%) of 23 patients with genotyping information; family history of GD; treatment status with imiglucerase (14 patients) and/or velaglucerase alfa (13 patients); hemoglobin concentrations, platelet counts, hepatomegaly and splenomegaly
GAUCHERITE, 42 patients with neuronopathic GD (16 male and 26 female), nine died (age of death 4 - 28 years), living patients aged 6-61yrs Multi-centre cohort study in England with retrospective and prospective clinical evaluation; registered with ClinicalTrials.gov, NCT code, 03240653 Clinical categorization as attenuated, intermediate and severe and on basis of defined pathogenic variants in GBA1; childhood disease manifestations for prognostic utility; phenotypic spectrum and clinical diversity

Infilbray's Safety Profile and Regulatory Significance for GD3

Trials evaluating treatments for neurological manifestations of Gaucher disease type 3 (GD3) have reported generally acceptable tolerability with no treatment-related serious safety signals. Across the LEAP trial, ambroxol programs, and combination or transplant approaches, severe adverse events were uncommon and discontinuations due to safety were not observed.

  • In the Phase 2, open-label LEAP trial (NCT02843035) of orally administered venglustat 15 mg once-daily in combination with maintenance dose of imiglucerase enzyme replacement therapy during 1 year of treatment in 11 adults with Gaucher disease type 3, there were no deaths, serious adverse events or discontinuations, with acceptable safety and tolerability.

  • In an investigator-initiated registry of ambroxol in Gaucher disease and GBA related Parkinson including 27 with neuronopathic GD, one patient with type 2 GD died of her disease, no other severe AEs were reported, and twelve patients experienced AE, including minor bowel discomfort, cough, allergic reaction, mild proteinuria, dizziness and disease progression.

  • In a systematic review of high-dose ambroxol therapy for Gaucher disease type 2 and 3 including eight clinical studies, no severe adverse events were reported, while clinical trials observed reduced lyso-GL1 levels in plasma (41-89%) and cerebrospinal fluid (CSF) (26-97%), alongside increased GCase activity in GD3 patients.

  • In combination and transplant studies in GD3, after 2 years of combined miglustat (200 mg, 3 t.i.d.) and imiglucerase (60 IU/kg every 2 weeks) no significant adverse effects were observed, and in four patients with GD3 undergoing enzyme replacement therapy followed by hematopoietic stem cell transplantation, chronic graft-versus-host disease occurred in one patient, none of the patients with GD3 had seizures or additional neurological symptoms after HSCT, but showed varying degrees of cognitive impairment.

Frequently Asked Questions

What is the mechanism of action of venglustat in addressing Gaucher disease pathology?
Venglustat functions as a glucosylceramide synthase inhibitor, which reduces the production of glucosylceramide. This substrate reduction therapy aims to decrease the accumulation of glucocerebroside, the primary storage material in Gaucher disease. By lowering substrate levels, it seeks to mitigate cellular dysfunction, particularly in tissues like the central nervous system.
What are the current unmet needs in treating the neurological manifestations of Type 3 Gaucher disease?
Current therapeutic approaches, such as enzyme replacement therapy, have limited ability to cross the blood-brain barrier, leaving neurological symptoms largely unaddressed. Patients with Type 3 Gaucher disease experience progressive neurological decline, including cognitive impairment, ataxia, and seizures. There is a significant need for therapies that can effectively target and reduce substrate accumulation within the central nervous system.
How does venglustat's therapeutic approach differ from enzyme replacement therapy for Gaucher disease?
Venglustat, as a substrate reduction therapy, inhibits the synthesis of the accumulating lipid, glucocerebroside, rather than replacing the deficient enzyme. This systemic approach allows for potential penetration into the central nervous system, which is a significant advantage over enzyme replacement therapies. ERT primarily addresses systemic manifestations but has limited efficacy against neurological symptoms due to poor blood-brain barrier permeability.
What is the potential clinical impact of venglustat on the progression of neurological symptoms in Type 3 Gaucher disease?
Venglustat aims to slow or halt the progression of neurological symptoms by reducing the accumulation of glucocerebroside in the brain. This could potentially improve cognitive function, motor skills, and overall quality of life for patients. Effective central nervous system penetration is crucial for mitigating the debilitating neurological decline characteristic of Type 3 Gaucher disease.

References

  1. [1] Cullufi P, Velmishi V et al.. Phenotypic Spectrum of Type 2-3 Gaucher Disease: A Case Study in the Balkan Genotype. The American journal of case reports. 2026 Jan 15. 41536045
  2. [2] Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. Expert review of clinical pharmacology. 2018 Dec. 30444430
  3. [3] Lachmann RH. Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain. Expert review of endocrinology & metabolism. 2009 May. 30743792
  4. [4] Pastores GM. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2010 Feb 1. 20055531
  5. [5] Zimran A, Durán G et al.. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease. Blood cells, molecules & diseases. 2019 Sep. 27499018
  6. [6] Zimran A, Elstein D. Management of Gaucher disease: enzyme replacement therapy. Pediatric endocrinology reviews : PER. 2014 Sep. 25345089
  7. [7] Vairo F, Netto C et al.. Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD reports. 2013. 23430813
  8. [8] Eghbali A, Hassan S et al.. Ophthalmological findings in Gaucher disease. Molecular genetics and metabolism. 2019 May. 31047801
  9. [9] Elstein D, Mehta A et al.. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. American journal of hematology. 2015 Jul. 25776130
  10. [10] Lee JY, Lee BH et al.. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean journal of pediatrics. 2012 Feb. 22375149
  11. [11] Zimran A, Gonzalez-Rodriguez DE et al.. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood cells, molecules & diseases. 2015 Jan. 25453586
  12. [12] Cook A, Stuart B et al.. Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N-of-1 Trial with 21 months Clinical Observation. Neurology and therapy. 2026 Feb. 41212481
  13. [13] Hughes DA, Gonzalez DE et al.. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. American journal of hematology. 2015 Jul. 25801797
  14. [14] Anurathapan U, Tim-Aroon T et al.. Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3. Pediatric blood & cancer. 2023 Mar. 36562549
  15. [15] Puri RD, Kapoor S et al.. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian pediatrics. 2018 Feb 15. 29503270
  16. [16] Bernardi S, Gemignani F et al.. The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis. Neurobiology of disease. 2023 Sep. 37573956
  17. [17] Deegan P, Lau H et al.. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry. Journal of clinical medicine. 2024 May 9. 38792324
  18. [18] El-Beshlawy A, Tylki-Szymanska A et al.. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular genetics and metabolism. 2017 Jan-Feb. 28040394
  19. [19] Ida H, Tanaka A et al.. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months. Blood cells, molecules & diseases. 2016 Jul. 27241455

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts